−0.171CHF
−20.80 MCHF
1.44 MCHF
73.70 M
About ADDEX THERAPEUTICS
Sector
CEO
Timothy Dyer
Headquarters
Geneva
Website
Employees (FY)
24
Founded
2002
ISIN
CH0029850754
FIGI
BBG006M6ZCZ5
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of APE is 0.128 CHF — it has decreased by 3.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ADDEX THERAPEUTICS stocks are traded under the ticker APE.
ADDEX THERAPEUTICS is going to release the next earnings report on Apr 18, 2024. Keep track of upcoming events with our Earnings Calendar.
APE stock is 3.91% volatile and has beta coefficient of 1.34. Check out the list of the most volatile stocks — is ADDEX THERAPEUTICS there?
One year price forecast for ADDEX THERAPEUTICS has a max estimate of 0.160 CHF and a min estimate of 0.160 CHF.
APE earnings for the last quarter are −0.04 CHF whereas the estimation was −0.01 CHF which accounts for −499.97% surprise. Estimated earnings for the next quarter are −0.01 CHF. See more details about ADDEX THERAPEUTICS earnings.
ADDEX THERAPEUTICS revenue for the last quarter amounts to 632.00 K CHF despite the estimated figure of 300.00 K CHF. In the next quarter revenue is expected to reach 600.00 K CHF.
Yes, you can track ADDEX THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
APE stock has risen by 96.92% compared to the previous week, the month change is a 96.92% rise, over the last year ADDEX THERAPEUTICS has showed a 12.33% decrease.
APE net income for the last quarter is −2.62 M CHF, while the quarter before that showed −2.68 M CHF of net income which accounts for 2.17% change. Track more ADDEX THERAPEUTICS financial stats to get the full picture.
Today ADDEX THERAPEUTICS has the market capitalization of 22.96 M, it has increased by 31.63% over the last week.
No, APE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, APE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ADDEX THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 24.00 employees. See our rating of the largest employees — is ADDEX THERAPEUTICS on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ADDEX THERAPEUTICS technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ADDEX THERAPEUTICS stock shows the buy signal. See more of ADDEX THERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ADDEX THERAPEUTICS future price: according to them, APE price has a max estimate of 0.16 CHF and a min estimate of 0.16 CHF. Read a more detailed ADDEX THERAPEUTICS forecast: see what analysts think of ADDEX THERAPEUTICS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ADDEX THERAPEUTICS EBITDA is −10.80 M CHF, and current EBITDA margin is −1.40 K%. See more stats in ADDEX THERAPEUTICS financial statements.